Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the febrile neutropenia market right now?

The size of the febrile neutropenia market has seen a robust increase in recent years. Expected to rise from $10.60 billion in 2024 to $11.31 billion in 2025, it’s with a compound annual growth rate (CAGR) of 6.7%. The escalation in the previous period is credited to the increased occurrence of cancer, the widespread acceptance of chemotherapy, the enlargement of customized medicine, decreasing healthcare expenses, and the rising prevalence of neutropenia.

How fast Is the febrile neutropenia market expected to grow, and what’s its future value?

Anticipations suggest a robust expansion in the febrile neutropenia market in the ensuing years. The market size is predicted to hit $14.48 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.4%. The predicted growth over the forecast period is largely owing to the rising consumption of immunosuppressive medications, the increase in research and development activities, favorable reimbursement schemes, and growing investments. Additionally, an upsurge in leukemia cases also contribute to this growth. Significant trends expected to be seen during the forecast period include the swift progression in molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, the use of immunotherapy and targeted treatments, the implementation of risk stratification models, and advancement in the field of fungal biomarkers.

Get your febrile neutropenia market report here!

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

What are the leading drivers of growth in the febrile neutropenia market?

The febrile neutropenia market is anticipated to grow, driven by the escalating cases of cancer. Cancer involves several diseases marked by uncontrolled growth of abnormal cells that have the potential to infiltrate nearby cells and disseminate to various parts of the body. The surge in cancer cases attributes to elements like aging population, exposure to environment and occupation, genetic vulnerability, and hormonal & reproductive aspects. Febrile neutropenia aids cancer patients by indicating the amplification of infection risk during chemotherapy. This catalyzes prompt intervention and precise treatments to avert severe implications, consequently upgrading patient prognosis and facilitating the continuation of cancer treatment on time. For instance, the American Cancer Society, a non-profit organization in the US advocating cancer consciousness, projected in January 2022 that the US will see approximately 1.9 million fresh cancer patients and 609,360 cancer-associated fatalities, resulting in nearly 1,670 deaths daily. Hence, the rising incidence rate of cancer is fueling the augmentation of the febrile neutropenia market.

What are the key segments defining the febrile neutropenia market?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Who are the key players steering the development of the febrile neutropenia market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

What are the key trends shaping the future of the febrile neutropenia market?

The primary focus for prominent firms in the febrile neutropenia market is to create advanced biosimilar drugs to increase the availability of treatment. Biosimilar drugs are biologics, highly similar to approved reference drugs in terms of structure, efficacy, and function. These are more affordable alternatives to original biologics, thus boosting patient accessibility while conforming to stringent regulatory standards. For example, in September 2022, the U.S. Food and Drug Administration (FDA) granted approval to Fresenius Kabi, a pharmaceutical company based in Germany, for its biosimilar Stimufend (pegfilgrastim-fpgk). This approval permits the usage of Stimufend in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy, which may result in febrile neutropenia, a severe condition marked by fever and low white blood cell count. Fresenius Kabi intends to introduce Stimufend in a pre-filled syringe format in early 2023, and is also in the process of creating an on-body injector for future utilization.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187

Which regions are most influential in expanding the febrile neutropenia market?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Diffuse Large B-Cell Lymphoma Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Follicular Lymphoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Foot And Mouth Disease Vaccine Global Market Report 2025

https://thebusinessresearchcompany.com/report/foot-and-mouth-disease-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: